E형 간염 진단 검사 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Hepatitis E Diagnostic Tests Market Size, Share & Trends Analysis Report By Type (ELISA HEV IgM Test, Rapid Diagnostics Test), By End-use (Hospitals, Blood Banks), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,299,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,694,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,484,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

E형 간염 진단 검사 시장 동향 :

세계의 E형 간염 진단 테스트 시장 규모는 2024년 5,710만 달러로 평가되며, 2025-2030년 4.8%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다.

세계에서 E형 간염의 확산, 특히 개발도상국에서의 확산이 진단 검사에 대한 수요를 크게 견인하고 있습니다. 공중보건 캠페인과 정보 접근성 향상으로 E형 간염에 대한 인식이 높아짐에 따라 조기 발견과 치료를 받으려는 사람들이 늘어나고 있습니다. 이러한 인식 증가는 진단 검사의 채택을 촉진하고 시장 확대에 기여하고 있습니다. 또한 대규모 감염 예방과 의료 인프라 개선에 중점을 두고 있는 것도 검사 기술의 지속적인 발전과 함께 E형 간염 진단 검사 시장의 성장을 더욱 촉진하고 있습니다.

또한 첨단 분자 기술, 신속 검사 플랫폼, 현장진단(POC) 솔루션과 같은 진단 기술 혁신은 E형 간염의 검출을 크게 향상시킬 수 있습니다. 원격지 및 자원이 부족한 지역에서 빠른 결과를 원하므로 POC 진단에 대한 선호도가 높아져 시장 성장을 더욱 촉진하고 있습니다. 의료 시스템이 조기 진단과 적시 개입을 우선시함에 따라 E형 간염 진단 검사 시장은 향후 수년간 크게 성장할 것으로 예상됩니다.

목차

제1장 분석 방법·범위

제2장 개요

제3장 E형 간염 진단 검사 시장 : 변동 요인·경향·범위

• 시장 연관 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석

제4장 E형 간염 진단 검사 시장 : 유형별 비즈니스 분석

• 시장 점유율 : 유형별(2024년·2030년)
• 유형별 대시보드
• 시장 규모 예측과 동향 분석 : 유형별(2018-2030년)
• ELISA HEV IgM 검사
• ELISA HEV IgG 검사
• 신속 진단 검사
• 중합효소 연쇄 반응(PCR)

제5장 E형 간염 진단 검사 시장 : 최종 용도별 비즈니스 분석

• 시장 점유율 : 최종 용도별(2024년·2030년)
• 최종 용도별 대시보드
• 시장 규모 예측과 동향 분석 : 최종 용도별(2018-2030년)
• 병원
• 진단 검사실
• 혈액은행
• 기타

제6장 E형 간염 진단 검사 시장 : 지역별 추정·동향 분석

• 시장 점유율 : 지역별(2024년·2030년)
• 시장 대시보드 : 지역별
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 참여 기업의 개요
• 기업의 시장 현황 분석
• 기업 분류
• 전략 지도제작
• 기업 개요/상장기업
  • Wantai BioPharm
  • MP Biomedicals LLP
  • PerkinElmer, Inc
  • Dia.Pro Diagnostic Bioprobes srl
  • ELITechGroup
  • Primerdesign Ltd
  • F. Hoffmann-La Roche Ltd
  • Mikrogen GmbH
  • Altona Diagnostics
  • Fortress Diagnostics

KSA

영문 목차

영문목차

Hepatitis E Diagnostic Tests Market Trends:

The global hepatitis E diagnostic tests market size was valued at USD 57.1 million in 2024 and is projected to witness a CAGR of 4.8% from 2025 to 2030. The growing prevalence of Hepatitis E globally, especially in developing regions, significantly drives the demand for diagnostic tests. As the awareness surrounding Hepatitis E increases due to public health campaigns and improved access to information, more individuals are seeking early detection and treatment. This heightened awareness is boosting the adoption of diagnostic tests, contributing to the market's expansion. Additionally, the emphasis on preventing outbreaks and improving healthcare infrastructure further stimulates the growth of the Hepatitis E diagnostic test market, with continued advancements in testing technology.

In addition, innovations in diagnostic technologies, such as advanced molecular techniques, rapid testing platforms, and point-of-care (POC) solutions, significantly enhance the detection of hepatitis E. These advancements offer faster, more accurate, cost-effective diagnostics, which are expected to increase market demand. The surge in preference for POC diagnostics, driven by the need for quick results in remote or resource-limited areas, further boosts market growth. As healthcare systems prioritize early diagnosis and timely interventions, the hepatitis E diagnostic tests market is poised for substantial expansion in the years ahead.

Global Hepatitis E Diagnostic Tests Market Report Segmentation

This report forecasts revenue and volume growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global hepatitis E diagnostic tests market report based on type, end-use, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)
• ELISA HEV IgM Tests
• ELISA HEV IgG Tests
• Rapid Diagnostics Tests
• Polymerase Chain Reaction (PCR)
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Diagnostics Laboratories
• Blood Banks
• Others
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Hepatitis E Diagnostic Tests Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Hepatitis E Diagnostic Tests Market: Type Business Analysis

• 4.1. Type Market Share, 2024 & 2030
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. ELISA HEV IgM Tests
  • 4.4.1. ELISA HEV IgM Tests Market, 2018 - 2030 (USD Million)
• 4.5. ELISA HEV IgG Tests
  • 4.5.1. ELISA HEV IgG Tests Market, 2018 - 2030 (USD Million)
• 4.6. Rapid Diagnostics Tests
  • 4.6.1. Rapid Diagnostics Tests Market, 2018 - 2030 (USD Million)
• 4.7. Polymerase Chain Reaction (PCR)
  • 4.7.1. Polymerase Chain Reaction (PCR) Market, 2018 - 2030 (USD Million)

Chapter 5. Hepatitis E Diagnostic Tests Market: End Use Business Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. End Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals market, 2018 - 2030 (USD Million)
• 5.5. Diagnostics Laboratories
  • 5.5.1. Diagnostics Laboratories Market, 2018 - 2030 (USD Million)
• 5.6. Blood Banks
  • 5.6.1. Blood Banks Market, 2018 - 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Hepatitis E Diagnostic Tests Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. UK Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Denmark Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Norway Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Sweden Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. South Korea Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. Australia Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Thailand Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Hepatitis E Diagnostic Tests Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Wantai BioPharm
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. MP Biomedicals LLP
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. PerkinElmer, Inc
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Dia.Pro Diagnostic Bioprobes srl
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. ELITechGroup
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Primerdesign Ltd
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. F. Hoffmann-La Roche Ltd
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Mikrogen GmbH
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Altona Diagnostics
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Fortress Diagnostics
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives

관련자료